Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Zollinger-Ellison Syndrome 1Vipoma 1Somatostatinoma 1Small Cell Lung Carcinoma 1Pheochromocytoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Insulinoma 1Glucagonoma 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoid Tumor 1Adrenal Cortex Neoplasms 1

Interventions

pembrolizumab 2Etoposide 2Cisplatin 2veliparib 1taxane 1liposomal doxorubicin 1Vinorelbine 1RRx-001 1Quality of Life 1Podophyllotoxin 1Platinum 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1PT-100 dipeptide 1Nivolumab 1Molecular Diagnostic Techniques 1Irinotecan 1Ipilimumab 1Immunotherapy 1Gemcitabine 1Drug Therapy 1Carboplatin 1Biological Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × veliparib × Endocrine × Clear all
NCT01642251 2023-05-06

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
156 enrolled 13 charts
EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Neuroendocrine, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡